Introduction
Each year, more deaths are caused by ovarian cancer than by any other gynecologic malignancy. Furthermore, ovarian cancer is the sixth most common cancer among women worldwide 1 Neoadjuvant chemotherapy (NACT) with a taxane and platinum-based regimen has recently been recommended for patients with advanced epithelial ovarian cancer (EOC) who cannot tolerate primary debulking surgery (PDS) and/or patients with advanced EOC for whom optimal cytoreduction is not feasible. For a select group of patients with advanced EOC, NACT has been recommended instead of exploratory laparotomy followed by adjuvant chemotherapy because NACT followed by interval debulking surgery (IDS) was shown to have fewer complications compared to PDS, without any statistically significant difference, in therapeutic efficacy in randomized trials 3 5 .
Cancer antigen 125 (CA 125), the protein encoded by the MUC16 gene, is the most frequently used tumor marker for ovarian cancer 6 . Because CA 125 is easily measured, simple to evaluate, and reflective of tumor growth, it is considered a particularly efficient method to evaluate treatment efficacy. Reductions in CA 125 levels before and after primary treatment (e.g., NACT or debulking surgery, followed by adjuvant chemotherapy) predicts the prognoses of advanced EOC patients 7 11 .
However, the correlation between post-NACT CA 125 levels and successful IDS remains controversial, despite a great deal of clinical interest.
To evaluate the associations between CA 125, surgical outcomes, and clinical outcomes, we retrospectively analyzed 107 patients with FIGO Stage III/IV EOC who were treated with NACT followed by IDS at the Kanagawa Cancer Center (Yokohama, Japan) over the past 12
years: January 2001 to December 2012.
Patients and Methods

Patients
In this study, we retrospectively enrolled 110 patients with presumed FIGO Stage III/IV EOC, based on the results of computed tomography/magnetic resonance im- Chicago, IL, USA).
Results
The mean patient age at diagnosis was 60. Patients were stratified into two groups, according to IDS evaluation ( Table 1) . We compared the clinical findings between these groups, including serum CA 125 levels (before and after NACT), progression-free survival were similar in both the complete/optimal IDS and suboptimal IDS groups.
Patients were also stratified into two groups according to post-NACT serum CA 125 levels: low-CA 125 (<35 U/ mL) and high-CA 125 (>100 U/mL; Table 2 ). The cutoff values for serum CA 125 levels were selected to provide comparisons of chemotherapy-susceptible and chemotherapy-resistant cases. We compared post-NACT serum CA 125 between the two groups in terms of complete/optimal IDS achievement rates and prognoses. Age, frequency of NACT administration, and pre-NACT serum CA 125 levels were similar in both groups.
When compared with the high-CA 125 group, the low- The survival rate also tended to be higher in the low-CA 125 group, although a statistically significant difference was not detected for OS (Fig. 1) .
Discussion
The prognosis of ovarian cancer is related to cytoreduction, which represents one of the most important treatment factors related to surgery and may even be important in cases of recurrent disease 12, 13 . Quality of life, efficacy of subsequent chemotherapy, and median survival each depend on residual tumor volume after cytoreductive surgery 14, 15 . To achieve maximum cytoreduction, NACT followed by IDS is often selected as the first treatment for advanced EOC.
No studies have included extensive investigations of the optimal timing of IDS during NACT and, indeed, this optimal timing remains to be clarified. However, some researchers have investigated correlations between the achievement of cytoreduction and changes in serum CA 125 levels. Rodriguez et al. 16 evaluated the relation- ship between mean serum CA 125 levels and surgical outcomes in a study of 103 patients with Stage IIIC/IV EOC who were treated with platinum-based NACT followed by IDS. The mean serum CA 125 levels prior to IDS differed significantly between the complete/optimal and suboptimal surgery groups (92 vs. 233 U/mL; p< 0.01). However, surgery groups did not differ significantly in terms of CA 125 levels at diagnosis (1,566 vs.
2,077 U/mL; p>0.05). Rodriguez et al. also noted that 38 patients (80%) in the complete surgery group had preoperative CA 125 levels of ! 100 U/mL, as compared to 33 patients (63.4%) in the optimal surgery group (p<0.05).
The results of the present study unequivocally support these prior findings. Additionally, we have shown that the mean CA 125 level prior to IDS is strongly associated with OS, as is particularly illustrated by our comparison of the high-CA 125 (>100 U/mL) and low-CA 125 (<35 U/mL) groups. The CA 125 cut-off value used by Rodriguez et al. 16 was substantially greater than that of the present study because Rodriguez et al. 16 included a median of 3 courses of NACT, whereas our study included a median of 6 courses. Vasudev et al. 18 reported that the regression rate of serum CA 125 levels during NACT had both prognostic and predictive value. However, our results do not support these prior findings, because we observed that the number of NACT courses required for serum CA 125 levels to halve or reduce to <35 U/mL was similar between the optimal/complete and the suboptimal surgery groups.
Therefore, we conclude that the pre-IDS value of serum CA 125 levels is more clinically important that the CA 125 reduction rate for successful cytoreduction after NACT.
Arits et al. 19 have questioned the ability of serum CA Although our study is limited by its rather small sample size, these findings could be instrumental in selecting the timing for IDS that is most likely to lead to an improved prognosis. Overall, our data suggest that post-NACT CA 125 levels of <35 U/mL can be used as a prognostic factor of a higher likelihood of optimal/complete IDS, which is known to be an independent predictor of survival for EOC patients with FIGO Stage III/IV regardless of the frequency of NACT administration.
However, it should be noted that the patients with post-NACT CA 125 levels of >100 U/mL are still candidates for IDS and hold a possibility of remission, because 6 patients out of 19 in the high-CA 125 group had achieved optimal/complete IDS. We hope that our data will contribute to further improvements in the prognosis of patients with advanced EOC, which accounts for >60% of all ovarian cancers, and who represent potential candidates for NACT-IDS. More investigation, however, will be required to further clarify these issues.
